Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen

Article

Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.

 

 

 

Recent Videos
Behind the Headlines episode 5
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Sanofi Invests €40 Million to Boost Antibody Production in France

Feliza Mirasol
November 21st 2024
Article

The investment will allow Sanofi to strengthen antibody bioproduction at its Lyon Gerland site in France.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Lecanemab Gets Nod from CHMP for Use in Early Alzheimer’s Disease

Felicity Thomas
November 15th 2024
Article

Eisai Europe and Biogen have received a positive opinion for the monoclonal antibody therapy to be used as a treatment of adult patients with early Alzheimer’s disease.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Aditum Bio and Leads Biolabs Form New Company, Oblenio Bio, for Developing a Therapeutic Antibody to Treat Autoimmune Disorders

Feliza Mirasol
November 7th 2024
Article

Under an agreement, Leads Biolabs has granted the new company, Oblenio Bio, an exclusive option to license LBL-051, a tri-specific T-cell engager antibody.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Lilly Forms Strategic Collaboration with ViaNautis Bio to Develop Novel Genetic Cargo-based Therapeutics

Feliza Mirasol
October 30th 2024
Article

The collaboration aims to develop precision genetic medicines using ViaNautis’ proprietary polyNaut technology platform.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics

Feliza Mirasol
October 28th 2024
Article

The companies expect to accelerate the clinical development of MRT-6160, a Phase I drug candidate, as well as explore further therapeutic opportunities across multiple indications.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Modifi Biosciences Acquired by Merck

Susan Haigney
October 24th 2024
Article

Merck is acquiring the Yale-spinout, which develops direct DNA modification-enabled cancer treatments.

© 2024 MJH Life Sciences

All rights reserved.